Synairgen plc (SYGGF)
Synairgen plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Southampton, LO, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $110,266. On trailing twelve-month figures it carries a trailing P/E of -0.23, a net margin of 0.0%. Its beta of 6.80 implies it has historically moved more than the broad market.
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.
Synairgen plc is most often compared with the following Healthcare names: